Articles published by Karuna Therapeutics, Inc.

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update

February 22, 2024

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

December 22, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers BMY KRTX

Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia

December 14, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

November 29, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

November 16, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates

November 02, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress

November 01, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics to Present at Upcoming Investor Conferences

November 01, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023

October 19, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress

October 04, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia

September 28, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics to Present at Upcoming Investor Conferences

August 30, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates

August 03, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Announces Leadership Appointments

August 03, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023

July 20, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

May 30, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting

May 22, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates

May 04, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics to Present at Upcoming Investor Conferences

May 02, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023

April 20, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

March 24, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics to Present at the Stifel 2023 CNS Days

March 23, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Announces Pricing of Public Offering of Common Stock

March 21, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Announces Proposed Public Offering of Common Stock

March 20, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia

March 20, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates

February 23, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates

February 02, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer

January 31, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer

December 06, 2022

From Karuna Therapeutics, Inc.

Via Business Wire

Tickers KRTX

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.